These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10282698)

  • 1. The cost of saving a life through cervical cytology screening: implications for health policy.
    Charny MC; Farrow SC; Roberts CJ
    Health Policy; 1987 Jun; 7(3):345-59. PubMed ID: 10282698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of costs and benefits of advances in cytologic technology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.
    Melamed MR; Hutchinson ML; Kaufman EA; Schechter CB; Garner D; Kobler TP; Krieger PA; Reith A; Schenck U
    Acta Cytol; 1998; 42(1):69-75. PubMed ID: 9479325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study.
    Boer R; de Koning H; Threlfall A; Warmerdam P; Street A; Friedman E; Woodman C
    BMJ; 1998 Aug; 317(7155):376-9. PubMed ID: 9694752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales.
    Martin-Hirsch P; Rash B; Martin A; Standaert B
    BJOG; 2007 Apr; 114(4):408-15. PubMed ID: 17378815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational care or rationing care? The case of cervical screening across the United Kingdom.
    Flynn H; Lewis P
    Health Policy; 2013 Oct; 112(3):197-201. PubMed ID: 23910733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model.
    Parkin DM; Moss SM
    J Epidemiol Community Health; 1986 Jun; 40(2):143-53. PubMed ID: 3746177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health economics analysis of cervical cancer screening].
    Boncz I; Sebestyén A; Pál M; Sándor J; Ember I
    Orv Hetil; 2003 Apr; 144(15):713-7. PubMed ID: 12774432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
    Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
    Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two view mammography at incident screens: cost effectiveness analysis of policy options.
    Johnston K; Brown J
    BMJ; 1999 Oct; 319(7217):1097-102. PubMed ID: 10531098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of cervical cancer screening for the elderly.
    Fahs MC; Mandelblatt J; Schechter C; Muller C
    Ann Intern Med; 1992 Sep; 117(6):520-7. PubMed ID: 1503355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of cervical cancer screening: health policy implications.
    Gyrd-Hansen D; Hølund B; Andersen P
    Health Policy; 1995 Oct; 34(1):35-51. PubMed ID: 10151964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cervical cancer epidemic that screening has prevented in the UK.
    Peto J; Gilham C; Fletcher O; Matthews FE
    Lancet; 2004 Jul 17-23; 364(9430):249-56. PubMed ID: 15262102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a proposed breast cancer screening regimen.
    Knox EG
    BMJ; 1988 Sep; 297(6649):650-4. PubMed ID: 3179545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic aspects of screening for cervical cancer in New Zealand.
    Bethwaite J; Rayner T; Bethwaite P
    N Z Med J; 1986 Oct; 99(811):747-51. PubMed ID: 3464889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effective policies for cervical cancer screening. An international review.
    Fahs MC; Plichta SB; Mandelblatt JS
    Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention.
    Raab SS; Zaleski MS; Silverman JF
    Am J Clin Pathol; 1999 Feb; 111(2):259-66. PubMed ID: 9930150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.